July 31, 2025

Germline BRCA Mutation Affect the Clinical Outcomes of Metastatic Breast Cancer Treated with CDK4/6 Inhibitor: A Real-world Study

View Full Paper

Ask AI

Bookmark

Authors

YSYingbo ShaoShanghai Institute of Organic Chemistry YHYaning HeAdvanced Energy Materials (United States)FGFangfang GuoZhengzhou University

Discussion

Member takes

Implication

Real-world analysis reveals germline BRCA mutation affects clinical outcomes in metastatic breast cancer treated with CDK4/6 inhibitors, suggesting implications for treatment strategies.

Key Points

Germline BRCA mutation may negatively influence clinical outcomes in metastatic breast cancer treated with CDK4/6 inhibitors.
Patients with gBRCA mutation had a median progression free survival of 9.2 months, compared to 18.5 months for gBRCA wt patients.
The objective response rate was 0% for gBRCA mutation patients, versus 35% for gBRCA wt, highlighting an efficacy difference.
Disease control rate for gBRCA mutation patients was 33.3%, significantly lower than 75% for gBRCA wt patients, indicating a treatment disparity.

Cite This Study

Shao et al. (2025) studied this question.

synapsesocial.com/papers/689a0c5fe6551bb0af8cf63d https://doi.org/10.21203/rs.3.rs-7072445/v1

View Full Paper

Ask AI

Bookmark

July 31, 2025

Germline BRCA Mutation Affect the Clinical Outcomes of Metastatic Breast Cancer Treated with CDK4/6 Inhibitor: A Real-world Study

View Full Paper

Ask AI

Bookmark

Authors

YSYingbo ShaoShanghai Institute of Organic Chemistry YHYaning HeAdvanced Energy Materials (United States)FGFangfang GuoZhengzhou University

Discussion

Member takes

Implication

Real-world analysis reveals germline BRCA mutation affects clinical outcomes in metastatic breast cancer treated with CDK4/6 inhibitors, suggesting implications for treatment strategies.

Key Points

Germline BRCA mutation may negatively influence clinical outcomes in metastatic breast cancer treated with CDK4/6 inhibitors.
Patients with gBRCA mutation had a median progression free survival of 9.2 months, compared to 18.5 months for gBRCA wt patients.
The objective response rate was 0% for gBRCA mutation patients, versus 35% for gBRCA wt, highlighting an efficacy difference.
Disease control rate for gBRCA mutation patients was 33.3%, significantly lower than 75% for gBRCA wt patients, indicating a treatment disparity.

Cite This Study

Shao et al. (2025) studied this question.

synapsesocial.com/papers/689a0c5fe6551bb0af8cf63d https://doi.org/10.21203/rs.3.rs-7072445/v1

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark